Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials
Morten Schmidt (),
Henrik Toft Sørensen and
Lars Pedersen
Additional contact information
Morten Schmidt: Aarhus University Hospital
Henrik Toft Sørensen: Aarhus University Hospital
Lars Pedersen: Aarhus University Hospital
Drug Safety, 2022, vol. 45, issue 9, No 6, 983-994
Abstract:
Abstract Introduction Diclofenac has increased cardiovascular risks, but its risk profile compared with other COX-2 inhibitors remains unknown. Aims The aim of this study was to compare the cardiovascular risks of diclofenac versus other older and newer COX-2 inhibitors (coxibs). Methods Using Danish nationwide health registries (1999–2020), we conducted a series of emulated trials (n = 264). Eligible adults had no recent NSAID prescriptions, contraindications or conditions with low adherence. We included initiators of diclofenac (n = 1,600,202), meloxicam (n = 10,903), etodolac (n = 238,538), celecoxib (n = 77,591), and etoricoxib (n = 12,122). We computed the adjusted intention-to-treat incidence rate ratio (aIRR) with 95% confidence interval (CI) of major adverse cardiovascular events (MACE) within 30 days of initiation (5562 events). Results MACE was 20% increased among initiators of diclofenac compared with other older COX-2 inhibitors (aIRR 1.19, 95% CI 1.10–1.28), driven by cardiac death (aIRR 1.57, 95% CI 1.21–2.03). The effect appeared strongest for women (aIRR 1.28, 95% CI 1.15–1.43), individuals with high baseline cardiovascular risk (aIRR 1.32, 95% CI 1.05–1.66), and when comparing high-dose diclofenac with low doses of the other older COX-2 inhibitors (aIRR 1.31, 95% CI 1.13–1.52). The results reflected increased rates compared with both meloxicam (aIRR 1.46, 95% CI 0.94–2.26) and etodolac (aIRR 1.18, 95% CI 1.09–1.28). Diclofenac initiators had similar increased rates of MACE compared with coxibs (aIRR 0.96, 95% CI 0.85–1.08), consistent for celecoxib (aIRR 1.02, 95% CI 0.88–1.19) and etoricoxib (aIRR 0.85, 95% CI 0.66–1.10). Conclusions The increased cardiovascular risks associated with diclofenac initiation were higher than for other older COX-2 inhibitors (meloxicam/etodolac) and comparable to coxibs (celecoxib/etoricoxib).
Date: 2022
References: View complete reference list from CitEc
Citations:
Downloads: (external link)
http://link.springer.com/10.1007/s40264-022-01211-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:45:y:2022:i:9:d:10.1007_s40264-022-01211-1
Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264
DOI: 10.1007/s40264-022-01211-1
Access Statistics for this article
Drug Safety is currently edited by Nitin Joshi
More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().